Keynote lecture by KateTx Chief Scientific Officer and Scientific Co-founder Sharif Tabebordbar, Ph.D., features non-human primate data demonstrating best-in-class potential of KT809, a novel muscle and heart-targeted, liver de-targeted development…
Read More
Strategic partnership leverages Capsida’s next-generation manufacturing capabilities to enable development of KateTx’s gene therapy medicines for muscle and heart diseases Capsida Biotherapeutics Inc. (“Capsida”) and Kate Therapeutics (“KateTx”) today announced…
Read More
Series A financing co-led by Westlake Village BioPartners and Versant Ventures Company advancing systemically delivered, skeletal and cardiac muscle targeted, liver de-targeted capsid and cargo technology platforms Initial pipeline addressing…
Read More
KT430 is a preclinical, next-generation investigational gene therapy to treat X-linked myotubular myopathy (XLMTM) Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), and Kate Therapeutics (“KateTx”) today…
Read More